期刊文献+

慢性心力衰竭急性失代偿期继续使用倍他乐克对心功能的影响 被引量:3

下载PDF
导出
摘要 目的探讨慢性稳定性心力衰竭已持续服用倍他乐克的患者,发生急性心功能失代偿时继续使用倍他乐克对心功能的影响。方法选取已服用倍他乐克1个月以上的慢性心力衰竭急性失代偿期患者23例,其中:15例心功能NYHAⅢ级的患者继续使用原倍他乐克剂量;8例NYHAⅣ级的患者减半量使用倍他乐克。观察入院2小时内、第24小时、第3天、第5天的BNP和NYHA心功能分级。与21例入院后即停用倍他乐克的对照组进行比较。结果两组患者的原发病、原服用倍他乐克剂量、入院时的BNP、NYHA分级等基本情况差异均无统计学意义(均P>0.05)。两组治疗后心功能均明显好转。观察组在入院第24小时、第3天、第5天的BNP和NYHA心功能分级与对照组比较,差异均无统计学意义(P>0.05);人均使用速尿针剂量较对照组大,但两组差异无统计学意义(P>0.05)。结论对已持续服用倍他乐克在中、重度慢性心力衰竭急性加重期无急性肺水肿的患者,只要细致观察、处理得当,继续审慎使用倍他乐克是可行的。
出处 《心脑血管病防治》 2012年第5期400-402,共3页 CARDIO-CEREBROVASCULAR DISEASE PREVENTION AND TREATMENT
  • 相关文献

参考文献7

  • 1无.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095. 被引量:3691
  • 2无.β肾上腺素能受体阻滞剂在心血管疾病应用专家共识[J].中华心血管病杂志,2009,37(3):195-209. 被引量:201
  • 3Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of meto- prolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomy- opathy(MDC) Trial Study Gmup[J]. Lancet, 1993,342:1441 - 1446.
  • 4Dickstein K, Cohen Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with file Hcart Faihtre Assoeiation of the ESC(I-IFA)and endorsed by the Euro- pean Society of Intensive Care Medicine(ESICM) [ J]. Eur Heart J, 2008,29 (19) :2388 - 2442.
  • 5陈雀敏,张健,韦丙奇,刘冰,黄燕,安涛,苏文亭.慢性心力衰竭急性失代偿患者口服小剂量β受体阻滞剂的血流动力学变化[J].中华老年多器官疾病杂志,2010,9(3):245-248. 被引量:10
  • 6Orso F, Baldasseroni S, Fabbri G, et al. Role of bern-blockers in patients admitted for worsening heart failure in a real world setting:data from the I- talian Survey on Acute Heart Failure[ J]. Eur J Heart Fail, 2009,11 ( 1 ) : 77 -84.
  • 7Yamaguchi H, Yoshida J, Yamamoto K, et al. Elevation of plasmabrain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy[J]. J Am Coil Cardiol,2004,43(1) :55 - 60.

二级参考文献72

共引文献3871

同被引文献30

  • 1王晓梅,吴焕淦,赵琛,周爽.红景天抗衰老作用研究概况[J].江苏中医药,2006,27(4):60-62. 被引量:15
  • 2陆在英,钟南山.内科学.北京:人民卫生出版社.[M].2008.4.第7版.17-21,61-78.
  • 3Maeder MT, Rickli H, Pfisterer ME, et al. Incidence, clinical predictors and prognostic impact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapy. Am Heart J, 2012,163:407-414.
  • 4Shore S, Aggarwal V, Zolty R. Carvedilol or sustained-release metoprolol for congestive heart failure: a comparative effective- ness analysis. J Card Fail,2012,18:919-924.
  • 5Shen X, Nair CK, Aronow WS, et al. Effect of carvedilol versus metoprolol CR/XL on mortality in patients with heart failure treated with cardiac resynchronization therapy: a COX multivari- ate regression analysis. Am J Ther, 2013,20 : 247-253.
  • 6Yancy CW, Jessup M, Bozkart B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Asso- ciation Task Force on Practice Guidelines. J Am Coil Cardiol, 2013,62 : e147-239.
  • 7中华医学会心血管分学会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014.中华心血管杂志,2014,42:98-122.
  • 8Babick A, Elimban V, Zieroth S, et al. Reversal of cardiac dys- function and subcellular alterations by metoprolol in heart failure due to myocardial infarction. J Cell Physiol,2013,228:2063- 2070.
  • 9James L, Januzzi Jr. The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use. Arc Cardiovas Dis, 2012,105:40-50.
  • 10Savarese G, Musella F, D' Amore C, et al. Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis. JACC Heart Fail, 2014,2 : 148-158.

引证文献3

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部